celiprolol Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Celiprolol is a medication in the class of beta blockers, used in the treatment of high blood pressure. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist.   Wikipedia

Chemistry

  • SMILES: CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(c1)C(=O)C
  • InChIKey: JOATXPAWOHTVSZ-UHFFFAOYSA-N
  • Mol. Mass: 379.5
  • ALogP: 2.89
  • ChEMBL Molecules:
    celiprolol  
    celiprolol hydrochloride  
More Chemistry

Pharmacology

Alternative names

celectol | celiprolol | celiprolol hcl | celiprolol hydrochloride | celiprolol monohydrochloride | dl-celiprolol | rs)-n'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-n,n-diethylurea | selecor | selectol

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (1)


 

Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Chromosome Aberrations (Phase 4)

Ehlers-Danlos Syndrome (Phase 4)

Hypertension ()

Postoperative Complications (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue